Immune Reconstitution Inflammatory Syndrome Reaction in Patient on Long-Term Prednisone

Area of Science:

• Immunology
• Infectious Diseases
• Pharmacology

Background:

• Immune reconstitution inflammatory syndrome (IRIS) is a clinical phenomenon often seen in patients with HIV initiating antiretroviral therapy or those discontinuing immunosuppressants.
• While triggers like tuberculosis (TB) therapy are known, less understood causes of IRIS persist.
• Polymyalgia rheumatica (PMR) management often involves long-term low-dose prednisone.

Observation:

• A case report details a patient with scrofula, indicative of TB reactivation.
• This patient subsequently developed IRIS.
• The patient was on long-term, low-dose prednisone for PMR management.

Findings:

• The IRIS presentation in this case is suspected to be linked to the concurrent use of rifampin for TB and prednisone.
• Rifampin may decrease the efficacy of prednisone, potentially leading to an exaggerated immune response and IRIS.
• This highlights a potential drug-drug interaction between rifampin and prednisone in the context of IRIS.

Implications:

• This case broadens the understanding of potential IRIS triggers, particularly in patients on chronic immunosuppression.
• It suggests a need for careful monitoring for IRIS in patients with TB and concurrent prednisone use, especially if rifampin is initiated.
• Further research into drug interactions between anti-TB medications and immunosuppressants like prednisone is warranted to optimize patient safety.